Loading…
AYTU
AYTU Biopharma Inc
NASDAQ· Healthcare· Drug Manufacturers - Specialty & Generic· CUSIP 054754858
$2.25+0.45%Price as of Aug 29, 18:37 UTC · updated once a day, after the close
Key metrics
- Market cap
- $24.15M
- P/E
- —
- Forward P/E
- —
- P/B
- 0.7x
- Dividend yield
- —
- Payout
- —
- EPS
- -$4.59
- ROE
- -97.42%
- Profit margin
- -60.17%
- Revenue growth
- -32.70%
- Beta
- 0.26
- 52-week high
- $3.07
- 52-week low
- $1.65
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -95.4% over 5Y.
today you would have $39.58▼ -96.0%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 19 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $2.28 | $2.60 | $1.70 | $2.84 | $3.80 | $27.00 | $119.60 | $194.00 | $158.00 | $8,920.00 | $96,000.00 | $3,600,000.00 | $2,224,390.25 | $4,097,561.00 | $8,195,122.00 |
Fair price, seven ways
Seven formulas applied to what the company reported. None of them predicts a price — each answers what the stock would be worth if its assumption held. The assumption is printed next to every number, because it is the assumption that produces the result.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Cash flow
$6.32
Cash flow growing 5.0% a year for 10 years, discounted at 10%, then 2.5% forever.
Operating
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| TVRDTvardi Therapeutics, Inc. | $1.82 | — | 1.2x | — | -126.19% | $24.28M |
| CLRBCellectar Biosciences, Inc. | $2.53 | — | 0.7x | — | -119.57% | $23.91M |
| NXTCNextCure, Inc. | $5.18 | — | 1.7x | — | -204.56% | $23.71M |
| DYAIDyadic International Inc | $0.61 |
About the company
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.
- 82
- Denver, United States
Company description provided by Yahoo Finance.